EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals

Eiichi Ogawa iD, Akira Kawano, Motoyuki Kohjima, Toshimasa Koyanagi, Kazufumi Dohmen, Aritsune Ooho, Takeaki Satoh, Kazuhiro Takahashi, Norihiro Furusyo, Eiji Kajiwara, Koichi Azuma, Yasunori Ichiki und 7 weitere

Journal of Gastroenterology and Hepatology · 2025-04 · 40 (4) · 971-978

DOI: 10.1111/jgh.16892 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 02.02.2025. Verfasst von Eiichi Ogawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim More accurate stratification of patients with chronic hepatitis C after permanent hepatitis C virus (HCV) clearance by direct‐acting antivirals (DAAs) is important for improving long‐term surveillance and treatment. The aim of this study was to stratify patients with chronic hepatitis C who are at risk of developing hepatocellular carcinoma (HCC) after HCV cure.

Methods

This multicenter, retrospective cohort study included 3177 consecutive adult chronic hepatitis C patients without decompensated cirrhosis who were treated with all‐oral DAAs. The primary study endpoints were long‐term cumulative de novo HCC incidence, HCC recurrence rates, and survival. Additionally, we analyzed the development of HCC by patients without cirrhosis, stratified by age and fibrosis status according to the FIB‐4 index.

Results

After exclusions, data from 3024 patients were available for analysis. The overall median follow‐up period was 6.5 years. None of the patients with non‐cirrhosis/FIB‐4 < 1.45 ( n = 475) developed HCC regardless of background factors. For patients with non‐cirrhosis/FIB‐4 ≥ 3.25, older age had a greater impact on HCC incidence (log‐rank test: p = 0.038). In addition, metabolic factors, including body mass index and diabetes mellitus, were not related to HCC incidence. HCC recurrence commonly occurred within 5 years after HCV cure; nevertheless, HCV cure contributed to an improvement of survival rates.

Conclusions

Age is a pivotal factor in predicting de novo HCC development following HCV cure in patients with moderate to advanced fibrosis. Conversely, patients with mild fibrosis (FIB‐4 < 1.45) may be eligible for discharge from specialized care after achieving HCV elimination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularLiver NeoplasmsHepatitis C, ChronicHumansMaleMiddle AgedFemaleRetrospective StudiesIncidenceAgedAdultTime FactorsLiver CirrhosisAge FactorsFollow-Up StudiesCohort StudiesHepacivirusNeoplasm Recurrence, Local

Stichwörter der Autor:innen

agedirect‐acting antiviralhepatitis C virushepatocellular carcinomamortalityrecurrencesurveillance

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
  • Department of Gastroenterology, NHO Kyushu Medical Center, Fukuoka, Japan.
  • Department of Internal Medicine, Fukuoka City Hospital, Fukuoka, Japan.
  • Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan.
  • Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan.

ORCID-Profile: Eiichi Ogawa, Rie Sugimoto, Masatake Tanaka

Zitieren

APA

Ogawa, E., Kawano, A., Kohjima, M., Koyanagi, T., Dohmen, K., Ooho, A., Satoh, T., Takahashi, K., Furusyo, N., Kajiwara, E., Azuma, K., Ichiki, Y., Sugimoto, R., Amagase, H., Senju, T., Tanaka, M., Nakamuta, M., Nomura, H., & Hayashi, J. (2025). Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals. Journal of Gastroenterology and Hepatology, 40(4), 971-978. https://doi.org/10.1111/jgh.16892

Vancouver

Ogawa E, Kawano A, Kohjima M, Koyanagi T, Dohmen K, Ooho A, et al. Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals. Journal of Gastroenterology and Hepatology. 2025;40(4):971-978. doi:10.1111/jgh.16892

BibTeX
@article{Ogawa2025,
  author = {Ogawa, Eiichi and Kawano, Akira and Kohjima, Motoyuki and Koyanagi, Toshimasa and Dohmen, Kazufumi and Ooho, Aritsune and Satoh, Takeaki and Takahashi, Kazuhiro and Furusyo, Norihiro and Kajiwara, Eiji and Azuma, Koichi and Ichiki, Yasunori and Sugimoto, Rie and Amagase, Hiromasa and Senju, Takeshi and Tanaka, Masatake and Nakamuta, Makoto and Nomura, Hideyuki and Hayashi, Jun},
  title = {Long‐Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct‐Acting Antivirals},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  volume = {40},
  number = {4},
  pages = {971--978},
  doi = {10.1111/jgh.16892}
}
Kostenlos starten →